CSL Limited (CMXHF)
CSL Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Melbourne, VIC, AU. The stock last traded at $98.03, up 0.77% on the session, giving a market capitalisation of $46.95B. On trailing twelve-month figures it carries a trailing P/E of 32.81, a net margin of 9.2%. Its beta of 0.08 implies it has historically moved less than the broad market.
CSL Limited is a global biopharmaceutical enterprise engaged in the discovery, development, production, marketing, and distribution of a wide array of medicinal and related products. Its operations span key markets including Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company's activities are organized into two primary divisions: CSL Behring and Seqirus. CSL Behring specializes in plasma-derived therapies, delivering essential plasma products and recombinant treatments designed to manage a range of serious conditions such as immunodeficiencies, various bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and certain neurological ailments. Beyond its therapeutic offerings, this division actively pursues research in both plasma and non-plasma-based treatments, and also generates revenue through licensing and royalties from its intellectual property commercialization. Meanwhile, Seqirus focuses on the manufacturing and distribution of non-plasma biotherapeutics, alongside the development of innovative influenza vaccines and related products. Established in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
CSL Limited is most often compared with the following Healthcare names: